RareCyte Publication Alert
Read the latest publication from RareCyte.
Journal of Clinical Oncology: Whole-slide biomarker quantitation in 82-patient NSCLC cohort study of acquired resistance to PD-(L)1 ICI therapy
Understanding the mechanisms of acquired resistance (AR) to immunotherapy is essential for the development of novel therapeutic strategies tailored to overcoming specific resistance mechanisms.
A recent publication in the ASCO Journal of Clinical Oncology highlights genomic and immunophenotypic heterogeneity of AR to PD-(L)1 immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC).
Samples from 82 patients with NSCLC and matched pre- and post-ICI biopsies were subjected to genomic profiling and to whole-slide biomarker quantitation at subcellular resolution using the Orion™ platform from RareCyte.
Immunophenotyping of matched pre- and post-ICI samples demonstrated significant decreases in intratumoral lymphocytes, CD3e+ and CD8a+ T cells, and PD-L1–PD1 engagement, as well as increased distance between tumor cells and CD8+PD-1+ T cells. There was a significant decrease in HLA class I expression in the immunotherapy cohort at the time of AR compared with control cohorts.
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer
Ricciuti B, Lamberti G, Puchala S, et al.
American Society of Clinical Oncology
Source: RareCyte
